Mark T. Osterman, MD, MSCE
Mark T. Osterman, MD, MSCE
Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Department: Medicine
Contact information
Penn Presbyterian Medical Center
Division of Gastroenterology
218 Wright-Saunders Building
51 North 39th Street
Philadelphia, PA 19104
Division of Gastroenterology
218 Wright-Saunders Building
51 North 39th Street
Philadelphia, PA 19104
Office: 215-662-8900
Fax: 215-662-0950
Fax: 215-662-0950
Email:
mark.osterman@uphs.upenn.edu
mark.osterman@uphs.upenn.edu
Publications
Links
Search PubMed for articles
Penn Presbyterian Medical Center
Penn Medicine at Radnor
Penn Medicine Inflammatory Bowel Disease Program
Search PubMed for articles
Penn Presbyterian Medical Center
Penn Medicine at Radnor
Penn Medicine Inflammatory Bowel Disease Program
Education:
BA (Chemistry)
Harvard University, 1995.
MD (Medicine)
Harvard Medical School, 1999.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2005.
Permanent linkBA (Chemistry)
Harvard University, 1995.
MD (Medicine)
Harvard Medical School, 1999.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2005.
Selected Publications
Lewis JD, Scott F, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Chen L, Yun Huifeng, Xie F, Curtis JR: Reduced mortality rates with anti-tumor necrosis factor alpha directed therapy when compared to prolonged corticosteroid therapy for inflammatory bowel disease. Gastroenterology 2017 Notes: Oral presentation at annual Digestive Diseases Week meeting May 2017.Herfarth HH, Jackson S, Schliebe B, Martin C, Ivanova A, Anton K, Sandler RS, Long MD, Isaacs KL, Osterman MT, Sands BE, Higgins PD, Lewis JD: Investigator initiated IBD trials in the US: Facts, obstacles and answers. Inflammatory Bowel Diseases 23(1): 14-22, 2017.
Papamichael K, Osterman MT, Cheifetz AS: Improved outcomes of proactive versus reactive therapeutic drug monitoring of infliximab in IBD. Clinical Gastroenterology and Hepatology 2017 Notes: In press.
Papamichael, Chachu KA, Vajravelu R, Vaughn B, Ni J, Osterman MT, Cheifetz AS: Proactive versus reactive therapeutic drug monitoring of infliximab in inflammatory bowel disease. Gastroenterology 2017 Notes: Poster presentation at annual Digestive Diseases Week meeting, Chicago IL, May 2017.
Papamichael, Chachu KA, Vajravelu R, Vaughn B, Ni J, Osterman MT, Cheifetz AS: Proactive compared to reactive therapeutic drug monitoring of infliximab is associated with less IBD-related surgery and hospitalization. Gastroenterology 2017 Notes: Poster presentation at annual Digestive Diseases Week meeting, Chicago IL, May 2017.
Osterman MT, Lichtenstein GR: Infliximab vs. Adalimumab for UC: Is There a Difference? Clinical Gastroenterology and Hepatology 2017 Notes: In press.
Papamichael K, Chachu KA, Vajravelu R, Vaughn BP, Ni J, Cheifetz AS, Osterman MT: Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared to reactive monitoring of serum concentrations of infliximab. Clinical Gastroenterology and Hepatology 2017 Notes: In press.
Cross RK, Osterman MT, Panaccione R, Afzali A, Song X, Shi N, Ding Y, Wang A: The Incidence of Cardiovascular Events in Patients with Crohn's Disease Treated with Vedolizumab and Anti-TNF Therapies. Gastroenterology 2017 Notes: Poster presentation for annual Digestive Diseases Week meeting, Chicago IL, May 2017.
Chachu KA, Osterman MT: How to diagnose and treat IBD mimics in the refractory IBD patient who does not have IBD. Inflammatory Bowel Diseases 22(5): 1262-74, May 2016.
Osterman MT, Lichtenstein GR: Chapter 116: Ulcerative Colitis. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, 10th Edition. Feldman M, Friedman LS, Brandt LJ (eds.). Saunders Elsevier, Philadelphia, Page: 2023-61, 2016.